An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970/M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors
Latest Information Update: 11 Feb 2022
At a glance
- Drugs Berzosertib (Primary) ; Carboplatin; Cisplatin; Etoposide; Gemcitabine; Irinotecan
- Indications Advanced breast cancer; Non-small cell lung cancer; Small cell lung cancer; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors EMD Serono Research & Development Institute; Merck KGaA; Vertex Pharmaceuticals
- 01 Jan 2022 Results (n=38) of phase 1b part of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer published in the Lung Cancer
- 26 May 2021 Results published in the British Journal of Cancer
- 26 May 2021 Results (n=31) of part B portion: berzosertib in combination with cisplatin, published in the British Journal of Cancer.